Cosmo N.V.

As of December 31, 2025, Cosmo Pharmaceuticals NV carries a market capitalization of 2.15B, placing it among publicly traded companies globally. Its enterprise value stands at 2.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cosmo Pharmaceuticals NV's next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Cosmo Pharmaceuticals NV has 16.19M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Cosmo Pharmaceuticals NV maintains a current ratio of 7.18, meaning it holds 7.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 21, 2026, Cosmo Pharmaceuticals NV's stock has declined approximately 22.55% over the past 52 weeks. The 50-day moving average sits at 68.37, while the 200-day moving average is 102.28.

As of December 31, 2025, Cosmo Pharmaceuticals NV holds 144.24M in cash and equivalents against 5.01M in total debt, resulting in a net debt position of -65.30M. Total book value stands at 566.68M, with working capital of 185.36M providing operational flexibility.